S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
NYSEAMERICAN:AMPE

Ampio Pharmaceuticals - AMPE Stock Forecast, Price & News

$0.10
0.00 (0.00%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.10
$0.11
50-Day Range
N/A
52-Week Range
$0.09
$1.83
Volume
6.37 million shs
Average Volume
3.46 million shs
Market Capitalization
$23.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Ampio Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,793.0% Upside
$3.00 Price Target
Short Interest
Healthy
5.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

AMPE stock logo

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Stock

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Stock News Headlines

Ampio Pharmaceuticals Issues Letter to Stockholders
6 Penny Stocks With 1,000% Upside Potential
Ampio Pharmaceuticals, Inc. to Hold Conference Call
AMPIO PROVIDES REGULATORY UPDATE
Ampio Pharmaceuticals GAAP EPS of -$0.10
See More Headlines
Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Company Calendar

Last Earnings
5/16/2022
Today
8/12/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSEAMERICAN:AMPE
CUSIP
03209T10
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+2,793.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.09 per share

Miscellaneous

Free Float
194,874,000
Market Cap
$23.47 million
Optionable
Optionable
Beta
1.51

Key Executives

  • Mr. Michael A. Martino (Age 65)
    CEO & Director
    Comp: $585.71k
  • Dr. David Bar-Or M.D. (Age 73)
    Founder & Chairman of Scientific Advisory Board
    Comp: $38.5k
  • Mr. Daniel G. Stokely CPA (Age 58)
    CPA, CFO, Corp. Sec. & Treasurer
    Comp: $301.36k
  • Dr. Howard Levy M.B.B.Ch. (Age 68)
    M.M.M., Ph.D., Chief Medical Officer
  • Lane Hapke
    VP of Manufacturing Operations
  • April Ramirez
    Clinical Trial Mang.
  • Laura Goldberg
    VP of Quality and Regulatory Operations













AMPE Stock - Frequently Asked Questions

Should I buy or sell Ampio Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMPE shares.
View AMPE analyst ratings
or view top-rated stocks.

What is Ampio Pharmaceuticals' stock price forecast for 2022?

1 Wall Street analysts have issued 12 month price targets for Ampio Pharmaceuticals' shares. Their AMPE share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 2,867.4% from the stock's current price.
View analysts price targets for AMPE
or view top-rated stocks among Wall Street analysts.

Are investors shorting Ampio Pharmaceuticals?

Ampio Pharmaceuticals saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 13,080,000 shares, a decline of 35.0% from the June 15th total of 20,130,000 shares. Based on an average daily volume of 4,510,000 shares, the short-interest ratio is presently 2.9 days. Currently, 15.1% of the shares of the stock are short sold.
View Ampio Pharmaceuticals' Short Interest
.

When is Ampio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our AMPE earnings forecast
.

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) issued its earnings results on Monday, May, 16th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01.

What other stocks do shareholders of Ampio Pharmaceuticals own?

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

Who are Ampio Pharmaceuticals' major shareholders?

Ampio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Courier Capital LLC (0.24%), Capital Wealth Alliance LLC (0.03%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Dan Stokely, Holli Cherevka and Philip H Coelho.
View institutional ownership trends
.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $0.10.

How much money does Ampio Pharmaceuticals make?

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) has a market capitalization of $22.88 million. The specialty pharmaceutical company earns $-15,890,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The official website for the company is ampiopharma.com. The specialty pharmaceutical company can be reached via phone at (720) 437-6500 or via fax at 720-437-6501.

This page (NYSEAMERICAN:AMPE) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.